The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
November 2nd 2024
The 11 to 3 vote against the benefit-risk profile of sotagliflozin comes with less than 2 months to go until the December 20, 2024 PDUFA date.
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Antihyperglycemic Agent Has No Cardiovascular Effect in Type 2 Diabetics
April 8th 2014Although the US Food and Drug Administration revised its approval processes for antihyperglycemic agents to include cardiovascular safety components, researchers still cannot discern whether those drugs affect cardiovascular outcomes.
Fish Oil Offers Cardioprotection in Post-op Atrial Fibrillation
April 4th 2014Up to 50% of patients who undergo bypass and heart valve surgeries develop postoperative atrial fibrillation, the result of which involves more postoperative complications, including stroke, longer hospital stays, and an increase in treatment costs.
Heartache Over New Cholesterol Treatment Guidelines
April 2nd 2014To produce the greatest impact from the implementation of the new American College of Cardiology and American Heart Association guidelines for the treatment of hypercholesterolemia in the primary prevention of cardiovascular disease (CVD), physicians should counsel patients on the benefits and risks of medication intervention to prevent CVD, but also explain the absolute necessity of regular exercise and abstention from tobacco use.
STAMPEDE Trial: Bariatric Surgery Beats Medical Management for Obese Patients with Diabetes
April 1st 2014Trial data presented at ACC.14 showed bariatric surgery was associated with much better long-term glycemic control in obese patients with diabetes compared with standard intensive medical therapy alone.
GIPS-III Trial: No Benefit from Post-Myocardial Infarction Metformin in Non-Diabetic Patients
April 1st 2014Trial results presented at ACC.14 demonstrated that treatment with metformin immediately after PCI in non-diabetic patients presenting with acute STEMI does not lead to improvements in left ventricular ejection fraction or other measure of cardiac function.
STABILITY Trial Results: Novel Plaque Inhibitor Darapladib Fails to Show Cardiovascular Benefit
April 1st 2014Darapladib, a novel agent targeting an enzyme known to be associated with increased instability of atherosclerotic plaque, failed to show real-world benefit in a large global trial examining mortality and coronary outcomes.
Sedentary Work Is More Damaging than Simple Inactivity
March 31st 2014As more patients work in sedentary occupations, the health of the general population has declined. Some studies have revealed that sedentary workers rarely compensate for their inactivity by increasing their exercise levels and/or reducing their sedentary behavior during leisure time.
Aleglitazar Does Not Improve Post-ACS Outcomes in Patients with Type 2 Diabetes
March 31st 2014The AleCardio trial was halted early due to safety concerns and lack of efficacy. Investigators reported patients with diabetes and acute coronary syndrome experienced elevated risk of heart failure, gastrointestinal hemorrhage, and renal dysfunction with no mitigating cardiovascular benefit.